Patents-Review.com
🔗 Permalink
Assignee profile:

AstraZeneca AB

City:

Sodertalje

Country:

Sweden

Published Applications:

1,861

Last publication date:

2026-06-11

Patent Grants:

1,104

Last grant date:

2025-09-16

AstraZeneca AB is a Swedish-British multinational pharmaceutical and biopharmaceutical company based in Sodertalje, SE. It is one of the world's largest pharmaceutical companies, with a portfolio of prescription medicines, vaccines, and consumer healthcare products. AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines for cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, neuroscience, and gastroenterology diseases. The company also has a strong presence in the biologics field with its own biosimilars portfolio.

Quarterly AstraZeneca AB Patent Applications

Top Inventors for applications by AstraZeneca AB

These are the the leading inventors for applications assigned to AstraZeneca AB:

Recent patent applications by AstraZeneca AB

AstraZeneca AB based in Sodertalje, SE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-06-11
US20260158022A1
Human necessities

ORAL FORMULATION OF A THERAPEUTIC COMPOUND

 #2 | 2025-08-28
US20250270248A1
Chemistry; metallurgy

OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS

 #3 | 2025-07-24
US20250235451A1
Human necessities

Methods of Delaying Pain Progression And Treating Prostate Cancer

 #4 | 2025-07-17
US20250228870A1
Human necessities

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS

 #5 | 2025-06-19 ✅ Patent 12,414,954 granted on 2025-09-16
US20250195530A1
Human necessities

POLQ INHIBITORS

 #6 | 2025-01-09 ✅ Patent 12,291,524 granted on 2025-05-06
US20250011311A1
Chemistry; metallurgy

Amido heteroaromatic compounds

 #7 | 2025-01-02 ✅ Patent 12,364,684 granted on 2025-07-22
US20250000848A1
Human necessities

PHARMACEUTICAL COMPOSITION

 #8 | 2024-12-26 ✅ Patent 12,318,367 granted on 2025-06-03
US20240423960A1
Human necessities

Pharmaceutical composition

 #9 | 2024-11-07 ✅ Patent 12,178,876 granted on 2024-12-31
US20240366768A1
Human necessities

Conjugates comprising cleavable linkers

 #10 | 2024-11-07 ✅ Patent 12,653,828 granted on 2026-06-16
US20240366615A1
Human necessities

POLQ INHIBITORS

 #11 | 2024-10-31 ✅ Patent 12,409,174 granted on 2025-09-09
US20240358698A1
Human necessities

COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES

 #12 | 2024-10-10 ✅ Patent 12,569,489 granted on 2026-03-10
US20240335446A1
Human necessities

1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE

 #13 | 2024-09-26
US20240317767A1
Chemistry; metallurgy

PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS

 #14 | 2024-09-12 ✅ Patent 12,240,832 granted on 2025-03-04
US20240300923A1
Chemistry; metallurgy

IRAK4 inhibitors

 #15 | 2024-08-01 ✅ Patent 12,201,638 granted on 2025-01-21
US20240252512A1
Human necessities

Pharmaceutical compositions comprising (2S)-n-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide

 #16 | 2024-06-27 ✅ Patent 12,473,272 granted on 2025-11-18
US20240208947A1
Chemistry; metallurgy

JAK1 SELECTIVE INHIBITORS

 #17 | 2024-06-06 ✅ Patent 12,448,385 granted on 2025-10-21
US20240182479A1
Chemistry; metallurgy

SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS

 #18 | 2024-05-23 ✅ Patent 12,613,173 granted on 2026-04-28
US20240167926A1
Physics

APPARATUS AND METHOD FOR EVALUATING PHYSICAL STRENGTH OR ROBUSTNESS OF SOLID PHARMACEUTICAL DOSAGE FORMS BASED ON AN IMPACT STRIKE TEST

 #19 | 2024-05-16 ✅ Patent 12,410,254 granted on 2025-09-09
US20240158519A1
Chemistry; metallurgy

TREATMENT OF CARDIOMETABOLIC DISEASE WITH INHIBITORS OF TYPE I INTERFERON SIGNALLING

 #20 | 2024-04-25 ✅ Patent 12,054,465 granted on 2024-08-06
US20240132455A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #21 | 2024-04-04 ✅ Patent 12,252,495 granted on 2025-03-18
US20240109902A1
Chemistry; metallurgy

Protein kinase B inhibitors

 #22 | 2024-03-14 ✅ Patent 12,472,194 granted on 2025-11-18
US20240082278A1
Human necessities

METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME

 #23 | 2024-02-29 ✅ Patent 12,620,146 granted on 2026-05-05
US20240070940A1
Physics

GRAPH CONSTRUCTION AND VISUALIZATION OF MULTIPLEX IMMUNOFLUORESCENCE IMAGES

 #24 | 2024-02-08
US20240041896A1
Human necessities

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS

 #25 | 2024-02-08 ✅ Patent 12,539,299 granted on 2026-02-03
US20240041858A1
Human necessities

ORAL FORMULATION OF A THERAPEUTIC COMPOUND

 #26 | 2024-02-08 ✅ Patent 12,220,403 granted on 2025-02-11
US20240041834A1
Human necessities

Pharmaceutical composition

 #27 | 2024-01-11 ✅ Patent 12,421,208 granted on 2025-09-23
US20240010631A1
Chemistry; metallurgy

CHEMICAL COMPOUNDS

 #28 | 2023-12-21 ✅ Patent 12,584,120 granted on 2026-03-24
US20230407285A1
Chemistry; metallurgy

PCSK9 INHIBITORS AND METHODS OF USE THEREOF

 #29 | 2023-11-16 ✅ Patent 12,060,429 granted on 2024-08-13
US20230365698A1
Chemistry; metallurgy

Method of treating type 1 interferon (IFN)-mediated disease using a subcutaneous dosing regimen comprising anifrolumab

 #30 | 2023-11-16 ✅ Patent 11,912,727 granted on 2024-02-27
US20230365599A1
Chemistry; metallurgy

Arginase inhibitors and methods of use thereof

 #31 | 2023-11-16 ✅ Patent 12,121,517 granted on 2024-10-22
US20230364077A1
Human necessities

Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases

 #32 | 2023-11-09 ✅ Patent 11,939,344 granted on 2024-03-26
US20230357279A1
Chemistry; metallurgy

Spirocyclic compounds

 #33 | 2023-09-07 ✅ Patent 11,773,069 granted on 2023-10-03
US20230278969A1
Chemistry; metallurgy

Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #34 | 2023-08-24 ✅ Patent 12,168,766 granted on 2024-12-17
US20230265428A1
Chemistry; metallurgy

Modulators of APOL1 expression

 #35 | 2023-08-10 ✅ Patent 12,364,689 granted on 2025-07-22
US20230248709A1
Human necessities

Dosage Regimen for the Treatment of Cancer

 #36 | 2023-07-13 ✅ Patent 12,024,523 granted on 2024-07-02
US20230219967A1
Chemistry; metallurgy

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

 #37 | 2023-06-15 ✅ Patent 12,065,496 granted on 2024-08-20
US20230183358A1
Chemistry; metallurgy

Antibody molecules and conjugates

 #38 | 2023-05-18 ✅ Patent 12,617,795 granted on 2026-05-05
US20230151013A1
Chemistry; metallurgy

FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS

 #39 | 2023-05-11 ✅ Patent 12,552,799 granted on 2026-02-17
US20230146796A1
Chemistry; metallurgy

TRIAZOLONE COMPOUNDS

 #40 | 2023-04-20 ✅ Patent 12,195,485 granted on 2025-01-14
US20230122859A1
Chemistry; metallurgy

Arginase inhibitors and methods of use thereof

 #41 | 2023-04-20
US20230119254A1
Chemistry; metallurgy

SYNERGISTIC AND TARGETING COMPOSITIONS FOR TREATMENT OF ARTERIAL AND VENOUS THROMBOSIS

 #42 | 2023-04-13 ✅ Patent 11,673,871 granted on 2023-06-13
US20230116721A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #43 | 2023-04-13 ✅ Patent 11,673,872 granted on 2023-06-13
US20230115170A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #44 | 2023-04-13 ✅ Patent 11,970,463 granted on 2024-04-30
US20230110122A1
Chemistry; metallurgy

Compounds and their use

 #45 | 2023-03-23 ✅ Patent 11,655,224 granted on 2023-05-23
US20230085620A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #46 | 2023-03-02 ✅ Patent 11,655,221 granted on 2023-05-23
US20230069044A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #47 | 2023-03-02 ✅ Patent 11,680,049 granted on 2023-06-20
US20230062646A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #48 | 2023-02-02
US20230035133A1
Chemistry; metallurgy

[1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases

 #49 | 2023-02-02 ✅ Patent 11,814,359 granted on 2023-11-14
US20230033573A1
Chemistry; metallurgy

Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #50 | 2023-01-26
US20230029336A1
Human necessities

Combination Therapy for Treating a Hematological Malignancy

 #51 | 2023-01-26 ✅ Patent 11,655,223 granted on 2023-05-23
US20230028726A1
Chemistry; metallurgy

Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #52 | 2023-01-26 ✅ Patent 11,655,222 granted on 2023-05-23
US20230025351A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #53 | 2022-12-29 ✅ Patent 12,502,398 granted on 2025-12-23
US20220409642A1
Human necessities

COMBINATION THERAPY FOR TREATING CANCER

 #54 | 2022-12-22
US20220401442A1
Human necessities

THERAPEUTIC COMBINATIONS OF ACALABRUTINIB AND CAPIVASERTIB TO TREAT B-CELL MALIGNANCIES

 #55 | 2022-12-01 ✅ Patent 12,084,437 granted on 2024-09-10
US20220380359A1
Chemistry; metallurgy

Halo-substituted piperidines as orexin receptor modulators

 #56 | 2022-09-01 ✅ Patent 12,115,174 granted on 2024-10-15
US20220273677A1
Human necessities

Dendrimer formulations

 #57 | 2022-07-21 ✅ Patent 12,606,555 granted on 2026-04-21
US20220227768A1
Chemistry; metallurgy

CHEMICAL COMPOUNDS

 #58 | 2022-07-21
US20220226438A1
Human necessities

COMPOSITIONS FOR SKIN AND WOUNDS AND METHODS OF USE THEREOF

 #59 | 2022-07-21
US20220226243A1
Human necessities

METHODS OF USING LIPID NANOPARTICLES FOR DELIVERING MODIFIED RNA ENCODING A VEGF-A POLYPEPTIDE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

 #60 | 2022-07-14 ✅ Patent 12,552,807 granted on 2026-02-17
US20220220122A1
Chemistry; metallurgy

PCSK9 INHIBITORS AND METHODS OF USE THEREOF

 #61 | 2022-07-14 ✅ Patent 11,760,760 granted on 2023-09-19
US20220220116A1
Chemistry; metallurgy

Protein kinase B inhibitors

 #62 | 2022-06-30 ✅ Patent 12,410,187 granted on 2025-09-09
US20220204527A1
Chemistry; metallurgy

FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS

 #63 | 2022-06-16 ✅ Patent 11,866,405 granted on 2024-01-09
US20220185817A1
Chemistry; metallurgy

Substituted indazoles as IRAK4 inhibitors

 #64 | 2022-06-09 ✅ Patent 12,465,608 granted on 2025-11-11
US20220175783A1
Human necessities

OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER

 #65 | 2022-05-26 ✅ Patent 11,738,027 granted on 2023-08-29
US20220160715A1
Human necessities

MPO inhibitors for use in medicine

 #66 | 2022-04-07 ✅ Patent 12,435,097 granted on 2025-10-07
US20220106335A1
Chemistry; metallurgy

ARGINASE INHIBITORS AND METHODS OF USE THEREOF

 #67 | 2022-03-31 ✅ Patent 11,847,415 granted on 2023-12-19
US20220100958A1
Physics

Automated detection of safety signals for pharmacovigilance

 #68 | 2022-03-24 ✅ Patent 11,840,689 granted on 2023-12-12
US20220090072A1
Chemistry; metallurgy

Method of treating fatty liver disease

 #69 | 2022-03-24 ✅ Patent 11,813,246 granted on 2023-11-14
US20220087982A1
Human necessities

Pharmaceutical composition

 #70 | 2022-02-17 ✅ Patent 11,970,530 granted on 2024-04-30
US20220048983A1
Chemistry; metallurgy

Methods of treating homologous recombination deficient cancer

 #71 | 2022-02-17 ✅ Patent 12,134,613 granted on 2024-11-05
US20220048904A1
Chemistry; metallurgy

Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof

 #72 | 2022-02-10 ✅ Patent 12,280,049 granted on 2025-04-22
US20220040173A1
Human necessities

Methods of delaying pain progression and treating prostate cancer

 #73 | 2022-01-27 ✅ Patent 12,213,988 granted on 2025-02-04
US20220023321A1
Human necessities

Methods of treating chronic kidney disease with dapagliflozin

 #74 | 2022-01-27 ✅ Patent 11,730,735 granted on 2023-08-22
US20220023295A1
Human necessities

Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases

 #75 | 2022-01-27 ✅ Patent 12,409,186 granted on 2025-09-09
US20220023252A1
Human necessities

Methods of treating chronic kidney disease with dapagliflozin

 #76 | 2022-01-13 ✅ Patent 11,795,158 granted on 2023-10-24
US20220009901A1
Chemistry; metallurgy

Chemical compounds

 #77 | 2021-12-02 ✅ Patent 12,059,424 granted on 2024-08-13
US20210369732A1
Human necessities

Pharmaceutical compositions comprising (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide

 #78 | 2021-11-18 ✅ Patent 11,691,978 granted on 2023-07-04
US20210355127A1
Chemistry; metallurgy

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

 #79 | 2021-11-11 ✅ Patent 12,115,225 granted on 2024-10-15
US20210346509A1
Human necessities

GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

 #80 | 2021-10-28 ✅ Patent 12,264,190 granted on 2025-04-01
US20210332105A1
Chemistry; metallurgy

Compositions and methods of treating cancer with chimeric antigen receptors

 #81 | 2021-10-28 ✅ Patent 11,952,392 granted on 2024-04-09
US20210332068A1
Chemistry; metallurgy

Arginase inhibitors and methods of use thereof

 #82 | 2021-10-28 ✅ Patent 12,453,729 granted on 2025-10-28
US20210330665A1
Human necessities

PHARMACEUTICAL FORMULATIONS

 #83 | 2021-10-21
US20210322415A1
Human necessities

METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB

 #84 | 2021-10-07 ✅ Patent 12,377,164 granted on 2025-08-05
US20210308275A1
Human necessities

Linkers and conjugates

 #85 | 2021-09-16 ✅ Patent 12,077,530 granted on 2024-09-03
US20210284636A1
Chemistry; metallurgy

Chemical compounds

 #86 | 2021-08-26 ✅ Patent 11,903,955 granted on 2024-02-20
US20210260083A1
Human necessities

Methods of treating heart failure with reduced ejection fraction

 #87 | 2021-08-05 ✅ Patent 11,667,615 granted on 2023-06-06
US20210238152A1
Chemistry; metallurgy

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

 #88 | 2021-07-29 ✅ Patent 11,472,816 granted on 2022-10-18
US20210230184A1
Chemistry; metallurgy

Mcl-1 inhibitors and methods of use thereof

 #89 | 2021-07-22 ✅ Patent 11,407,765 granted on 2022-08-09
US20210221823A1
Chemistry; metallurgy

Tetracyclic heteroaryl compounds

 #90 | 2021-07-15 ✅ Patent 11,434,236 granted on 2022-09-06
US20210214348A1
Chemistry; metallurgy

Halo-substituted piperidines as orexin receptor modulators

 #91 | 2021-07-01 ✅ Patent 12,516,304 granted on 2026-01-06
US20210198642A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR IMPROVED NUCLEASES

 #92 | 2021-07-01 ✅ Patent 11,883,582 granted on 2024-01-30
US20210196908A1
Human necessities

Inhaler

 #93 | 2021-06-10 ✅ Patent 11,352,369 granted on 2022-06-07
US20210171541A1
Chemistry; metallurgy

Pyridine and pyrimidine derivatives

 #94 | 2021-06-10 ✅ Patent 11,884,671 granted on 2024-01-30
US20210171525A1
Chemistry; metallurgy

Purinone compounds and their use in treating cancer

 #95 | 2021-05-20 ✅ Patent 11,613,539 granted on 2023-03-28
US20210147416A1
Chemistry; metallurgy

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

 #96 | 2021-05-20 ✅ Patent 11,382,951 granted on 2022-07-12
US20210145934A1
Human necessities

Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors

 #97 | 2021-05-06 ✅ Patent 11,685,953 granted on 2023-06-27
US20210130901A1
Chemistry; metallurgy

Biomarkers and methods of treating cancer

 #98 | 2021-05-06 ✅ Patent 11,524,951 granted on 2022-12-13
US20210130318A1
Chemistry; metallurgy

2-(2,4,5-substituted-anilino)pyrimidine compounds

 #99 | 2021-04-29 ✅ Patent 11,149,024 granted on 2021-10-19
US20210122735A1
Chemistry; metallurgy

Synthesis of Mcl-1 inhibitor

 #100 | 2021-04-29 ✅ Patent 11,180,477 granted on 2021-11-23
US20210122734A1
Chemistry; metallurgy

Process for the preparation of osimertinib (AZD9291) or a salt thereof, and “AZD9291 Aniline” or a salt thereof

Also check out AstraZeneca AB's (Sodertalje, Sweden) applicant profile with 424 patent applications submitted.

AssigneeID:

1914 ⎘